The role of vascular cell adhesion molecule 1/ very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium by Silverman, Matthew D. et al.
ARTHRITIS & RHEUMATISM
Vol. 56, No. 6, June 2007, pp 1817–1826
DOI 10.1002/art.22706
© 2007, American College of Rheumatology
The Role of Vascular Cell Adhesion Molecule 1/
Very Late Activation Antigen 4 in Endothelial Progenitor Cell
Recruitment to Rheumatoid Arthritis Synovium
Matthew D. Silverman,1 Christian S. Haas,1 Ali M. Rad,2 Ali S. Arbab,2 and Alisa E. Koch3
Objective. Marrow-derived endothelial progenitor
cells (EPCs) are important in the neovascularization
that occurs in diverse conditions such as cardiovascular
disorders, inflammatory diseases, and neoplasms. In
rheumatoid arthritis (RA), synovial neovascularization
propels disease by nourishing the inflamed and hyper-
proliferative synovium. This study was undertaken to
investigate the hypothesis that EPCs selectively home to
inflamed joint tissue and may perpetuate synovial neo-
vascularization.
Methods. In a collagen-induced arthritis (CIA)
model, neovascularization and EPC accumulation in
mouse ankle synovium was measured. In an antibody-
induced arthritis model, EPC recruitment to inflamed
synovium was evaluated. In a chimeric SCID mouse/
human synovial tissue (ST) model, mice were engrafted
subcutaneously with human ST, and EPC homing to
grafts was assessed 2 days later. EPC adhesion to RA
fibroblasts and RA ST was evaluated in vitro.
Results. In mice with CIA, cells bearing EPC
markers were significantly increased in peripheral
blood and accumulated in inflamed synovial pannus.
EPCs were 4-fold more numerous in inflamed synovium
from mice with anti–type II collagen antibody–induced
arthritis versus controls. In SCID mice, EPC homing to
RA ST was 3-fold greater than to normal synovium.
Antibody neutralization of vascular cell adhesion mole-
cule 1 (VCAM-1) and its ligand component 4 integrin
potently inhibited EPC adhesion to RA fibroblasts and
RA ST cryosections.
Conclusion. These data demonstrate the selective
recruitment of EPCs to inflamed joint tissue. The
VCAM-1/very late activation antigen 4 adhesive system
critically mediates EPC adhesion to cultured RA fibro-
blasts and to RA ST cryosections. These findings pro-
vide evidence of a possible role of EPCs in the synovial
neovascularization that is critical to RA pathogenesis.
Neovascularization is a hallmark of diverse
pathologic conditions, including rheumatoid arthritis
(RA) (1). Microcirculatory expansion occurs either
through angiogenesis (the proliferation and branching
off of preexisting microvessels) (2) or by vasculogenesis
(the de novo formation of blood vessels from circulating
endothelial progenitor cells) (EPCs) (3). Until recently,
neovascularization in adult tissue was thought to occur
exclusively through angiogenesis. The identification of
circulating bone marrow–derived EPCs (4) has resulted
in reevaluation of this classic paradigm of blood vessel
development.
The pathogenesis of RA is critically dependent
on neovascularization of the synovium, with microvascu-
lar expansion occurring before clinical symptoms appear
(5). Synovial neovascularization is of pivotal importance
in the progression of RA, in that it creates a direct
conduit for the entry into the joint of circulating leuko-
cytes that exacerbate inflammation, and provides nutri-
ents to the hyperproliferative synovium.
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EPCs have been described to accumulate in the
synovial pannus in RA (6). Explorations into the molec-
ular mechanisms by which EPCs are recruited from the
circulation to inflamed tissue remain limited, however.
In this study we demonstrated EPC homing to diseased
synovium in several models of inflammatory arthritis.
Our findings provide evidence of a primary role of the
vascular cell adhesion molecule-1 (VCAM-1)/4 inte-
grin ligand/receptor pair in mediating the adhesive in-
teractions between EPCs and inflamed synovial tissue
and cells.
MATERIALS AND METHODS
Materials. Polyclonal sheep anti-human intercellular
adhesion molecule 1 (ICAM-1) and VCAM-1 and goat anti-
human ICAM-2 and LYVE-1 (a lymphatic endothelial cell–
specific marker) were from R&D Systems (Minneapolis, MN).
Mouse monoclonal antibodies against human 4, L, and 2
integrins, and recombinant human tumor necrosis factor 
(TNF) were also from R&D Systems. Rabbit anti-human von
Willebrand factor (vWF) antibody was from Dako (Carpinte-
ria, CA). Fluorescein isothiocyanate (FITC)– or phycoerythrin
(PE)–conjugated mouse anti-human monoclonal antibodies
for flow cytometric analysis of 4, L, and 2 integrins, CD3,
CD4, CD8, CD14, CD19, CD31, and CD34, rat anti-mouse
monoclonal antibody CD117, stem cell antigen 1 (Sca-1), and
appropriate fluorescence-conjugated control antibodies were
from BD PharMingen (San Diego, CA). PE-conjugated mouse
anti-human CD133 was from Miltenyi Biotec, (Auburn, CA).
Fetal bovine serum (FBS), RPMI 1640 culture medium, and
phosphate buffered saline (PBS) were from Invitrogen (Carls-
bad, CA). Chicken type II collagen and Freund’s complete
adjuvant were from Chondrex (Redmond, WA). Carboxyfluo-
rescein diacetate succinimidyl ester (CFSE) was from Molec-
ular Probes (Eugene, OR). All other reagents were from
Sigma (St. Louis, MO).
Animals. DBA/1J mice were from Jackson Laborato-
ries (Bar Harbor, ME). BALB/c and SCID/NCr mice were
from the National Cancer Institute (Bethesda, MD). Animals
were maintained on a 12-hour light/12-hour dark cycle, and
received food and water ad libitum. Animal studies were
conducted under approval of the University of Michigan’s
University Committee on Use and Care of Animals.
Endothelial progenitor cells. Human cells and tissue
samples were obtained according to University of Michigan
and/or Henry Ford Health System Institutional Review Board–
approved protocols. CD133 leukocytes were purified from
cord blood obtained from anonymous donors within 24 hours
postpartum, using an immunomagnetic cell isolation kit
(Miltenyi Biotec). Human CD34 cells were obtained from
the National Disease Research Interchange (Philadelphia,
PA). Enriched human EPCs were 95% CD133, as deter-
mined by flow cytometry. Mouse progenitor cells, determined
based on their lack of expression of lineage markers (Lin),
were isolated from bone marrow from femurs, tibias, and
humeri of 6-week-old-male DBA/1J or BALB/c mice, using a
hematopoietic cell isolation kit (Stem Cell Technologies, Van-
couver, British Columbia, Canada). EPCs were used im-
mediately or were expanded up to 30-fold in culture, using
StemSpan progenitor cell media (Stem Cell Technologies)
containing 50 ng/ml recombinant human Flt-3 ligand, 50 ng/ml
recombinant human stem cell factor, and 50 ng/ml recombi-
nant human thrombopoietin (Stem Cell Technologies).
Synovial tissue and RA synovial fibroblast cultures.
RA synovial tissue (ST) was obtained from patients undergo-
ing arthroplasty or synovectomy. Normal ST was obtained at
autopsy or from patients undergoing amputation, within 24
hours after death or limb removal, respectively. For studies of
EPC adhesion to ST, tissue specimens were snap-frozen in
liquid nitrogen using OCT embedding medium (Sakura, Tor-
rance, CA), and were cut into 8-m cryosections just before
use. For mouse engraftment studies, ST samples were cut into
5-mm3 sections under aseptic conditions and were cryopre-
served in liquid nitrogen in 20% DMSO–80% FBS until used
in experiments. Human RA synovial fibroblasts were isolated
from RA ST using a solution of Dispase (2.4 mg/ml), type II
collagenase (250 units/ml), and DNase (1  104 units/ml) in
PBS, cultured in RPMI 1640 containing 10% FBS and 2 mM
L-glutamine, and used between passages 6 and 9.
Flow cytometry. After blocking in PBS containing 20%
FBS, EPCs (1  105–1  106) were stained in 200 l blocking
buffer containing a 1:50 dilution of the appropriate FITC- or
PE-conjugated antibodies. To evaluate nonspecific antibody
binding and for flow cytometer compensation adjustment, EPC
samples were separately stained with isotype-matched
fluorochrome-conjugated control antibodies, at the same
concentration/reaction volume as test samples. After staining,
EPCs were evaluated on an Epics XL flow cytometer (Beck-
man Coulter, Miami, FL). At least 104 events were recorded
for each sample, and all experiments were repeated at least 3
times.
Immunohistochemistry. Ankle cryosections from mice
with collagen-induced arthritis (CIA) were stained for vWF,
LYVE-1, or CD117 (c-Kit). For CD117 and LYVE-1 staining,
cryosections were blocked in Tris buffered saline (TBS) con-
taining 20% FBS. Primary antibodies were added for 30
minutes at 10 g/ml, followed by washing in TBS–0.1% Tween
20 (TBST). Appropriate alkaline phosphatase–conjugated sec-
ondary antibodies (Sigma) were added for 30 minutes at 1:100
dilutions in TBS, followed by TBST washing and addition of
the chromogenic substrate fast red (Pierce, Rockford, IL).
Sections were hematoxylin counterstained and evaluated by
brightfield microscopy. For vWF staining of blood vessels,
formalin-fixed, decalcified, paraffin-embedded sections of
mouse ankles were antigen-retrieved using a combination of
heat treatment (20 minutes at 80°C) (Target Retrieval Solu-
tion; Dako), and protease K treatment (10 g/ml in 10 mM
Tris HCl/1 mM EDTA [pH 8.0], for 20 minutes at 37°C). After
antigen retrieval, sections were washed with TBST, and the
staining protocol was resumed at the blocking step. For
assessment of vWF-positive blood vessel density, the mean
value from 10 sections per animal (n  14 hind limbs with
grade 3 arthritis and 4 control hind limbs) was determined at
the tibial/tarsal apposition. Micrographs of these sections were
simultaneously assessed for maximal synovial thickness at the
tibial/tarsal diarthrosis.
Collagen-induced arthritis. Female DBA/1J mice (6–8
weeks old) were injected intradermally at the base of the tail
with 100 l of a homogenized mixture of equal parts of chicken
type II collagen (2 mg/ml) dissolved in 0.05M acetic acid, and
Freund’s complete adjuvant containing 4 mg/ml heat-killed
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Mycobacterium tuberculosis. On day 21, mice were boosted with
an intraperitoneal injection of 100 g chicken type II collagen.
Arthritis severity was scored daily after the boosting injection,
by 1 or more observers, under blinded conditions. The scoring
system ranks arthritis on a score of 0 (no symptoms) to 3
(maximal inflammation) per assessed ankle (7). Mice were
killed at various time points between the day of arthritis onset
and 40 days post–symptom development. Paws were formalin
fixed or were cryopreserved in liquid nitrogen. In some cases,
peripheral blood was drawn for EPC analysis, at the time mice
were killed.
Antibody-induced arthritis. Eight week-old female
BALB/c mice were injected intraperitoneally with 200 l of a
cocktail containing 1 mg each of 4 different anti–type II
collagen monoclonal antibodies (Chemicon, Temecula, CA).
Three days later, animals were boosted with an intraperitoneal
injection of 50 g lipopolysaccharide (LPS) in PBS. In this
model, animals develop arthritis 1–2 days after receiving LPS,
with maximal symptoms observed 5–7 days after LPS admin-
istration. Two days after the LPS injection, animals received an
intravenous injection of 1  106 PKH26-labeled murine EPCs
in 200 l PBS. Control animals received vehicle injections.
Cells were allowed to circulate for 5 days, animals were killed,
and hind legs were snap frozen. Mouse ankle cryosections were
assessed for EPC accumulation in the tibial/tarsal synovium by
fluorescence microscopy, using a BX51 fluorescence micro-
scope with DP Manager imaging software (Olympus, Melville,
NY). At least 10 high-power fields (hpf) of 6 16-m–thick
sections were evaluated per animal. Only hind legs were
evaluated in this model, since the joints are larger than in the
front legs, and the synovium is more easily discernable.
SCID mouse/human ST chimera model. To observe
human EPC homing to human ST in an in vivo model, we
engrafted 0.5-mm3 pieces of either normal or RA human ST
subcutaneously on the backs of female 6-week-old SCID/NCr
mice. ST was engrafted for 2 weeks, after which 1  106
PKH26-labeled human CD34 cells or EPCs (CD133 cells)
were injected intravenously. Cells were allowed to circulate for
2 days, animals were killed, excised grafts were snap frozen,
and cryosections were evaluated for EPC accumulation by
fluorescence microscopy. At least 10 hpf of between 4 and 9
16-m–thick sections were evaluated per animal.
Enzyme-linked immunocellular assay. Confluent RA
ST fibroblast monolayers, cultured in 96-well tissue culture
plates, were treated with TNF for up to 24 hours. At the end
of the experiment, cells were fixed in 0.5% glutaraldehyde/
RPMI base medium, washed in PBS, and evaluated for
VCAM-1 and ICAM-1 cell surface expression by enzyme-
linked immunocellular assay, as described previously (8). Re-
sults are presented as arbitrary fluorescence units or as a
percentage of the indicated control (set at 100%). Background
fluorescence from wells in which the primary antibody was
omitted served as a control and was subtracted from experi-
mental values. Conditions were replicated in 4–6 wells per
experiment.
Western blot analysis. Western blotting for VCAM-1
and ICAM-1 was performed on lysates from TNF-stimulated
RA ST fibroblasts from 3 donors. Lysates were subjected to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis,
proteins were transferred to nitrocellulose, and membranes
were probed with VCAM-1 or ICAM-1 antibodies, followed by
probing with horseradish peroxidase–conjugated secondary
antibodies and development by chemiluminescence (Amer-
sham, Arlington Heights, IL). Immunoblots were reprobed
with rabbit anti-human -actin (Sigma) for normalization.
After digitization, band intensities were evaluated with UN-
Scan-It software (Silk Scientific, Orem, UT). Band intensity
corresponded to the sum of all pixel values in the selected
region minus the background pixel value, and is presented as a
ratio of VCAM-1 or ICAM-1 intensity to -actin intensity.
EPC adhesion to cultured RA ST fibroblasts. Conflu-
ent RA ST fibroblast monolayers in 96-well tissue culture
plates were stimulated with TNF in various concentrations
and for various lengths of time. RA ST fibroblasts were washed
3 times with RPMI–1% FBS. CFSE-labeled EPCs (50,000/
well) were adhered to RA ST fibroblasts in medium in 100
l/well for 20 minutes. In some experiments, neutralizing
antibodies against adhesion molecules and integrins were
mixed with the EPC suspension immediately prior to the
adhesion assay. Nonadherent EPCs were washed off with
media, and bound EPCs were quantified by measuring their
fluorescence using 485/530-nm excitation/emission wavelength
filters. RA ST fibroblast background autofluorescence was
subtracted from all experimental values. Conditions were
replicated in 4–6 wells per experiment.
EPC adhesion to ST cryosections. RA ST cryosections
(8 m) were rehydrated and overlaid with PKH26-tagged
EPCs in RPMI–1% FBS (150 l per section of a cell suspen-
sion of 50  105 EPCs/ml) that had been pretreated for 15
minutes with neutralizing sheep anti–VCAM-1, mouse anti–4
integrin monoclonal antibody, or the appropriate control IgG
(all at 10 g/ml). After 15 minutes, nonattached EPCs were
removed, and adherent EPCs in each section were counted by
fluorescence microscopy (9), under blinded conditions, in 5 hpf
(200 magnification), and the results averaged. Results are
presented as the percentage of maximal binding (100% [num-
ber of adherent EPCs/hpf in the presence of control IgG
antibody]).
Statistical analysis. Mean  SEM values were calcu-
lated. The significance of differences in mean values between
experimental and control groups was determined by Student’s
t-test. P values less than 0.05 were considered significant.
Linear regression was used to obtain goodness-of-fit (r2)
values.
RESULTS
Isolation and characterization of EPCs. En-
riched murine EPCs were consistently 95% Lin. The
EPC population (Lin,Sca-1,CD117) was enriched
10-fold, from 2% of total starting marrow cells to
25% (results not shown). We further characterized these
EPCs, by flow cytometry, as being 20% vascular
endothelial growth factor receptor 2 positive, 75%
CD31, and 50% CD34, consistent with expectations
for an enriched angioblast subset. With isolation of cord
blood CD133 EPCs, we typically obtained 1  106
CD133 EPCs per preparation, with a purity of 95%.
More than 90% of these cells expressed both CD34 and
CD31 on their surfaces, by flow cytometry, and these
cells were uniformly negative for the leukocyte matura-
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tion markers CD3, CD4, CD8, CD14, and CD19 (results
not shown).
Synovial neovascularization in CIA. In the CIA
model, arthritis incidence was nearly 100%, with disease
severity 50% of the maximum possible (Figure 1A).
Over time, the inflamed synovium thickened (Figure 1B)
and became heavily neovascularized (Figure 1C). In-
cluded in the synovial inflammatory infiltrate were nu-
merous CD117 putative EPCs (Figure 1E).
Flow cytometry revealed a mean  SEM 22 
Figure 1. Neovascularization in collagen-induced arthritis (CIA). A, Incidence and severity of CIA in 2 experiments. The CIA induction protocol
resulted in a high incidence of arthritis, but with variable severity and time to onset (n  15 mice in each experiment). Values are the percent
incidence and the mean arthritis severity score. B, Synovial thickness in mice with CIA. Sagittal sections of formalin-fixed hind ankles from 14
animals with CIA and 4 nonarthritic animals were assessed microscopically with a size-calibrated field of view for synovial thickness, and by
immunohistochemistry for von Willebrand factor (vWF)–positive vascular density. After development of CIA, the synovium continued to proliferate
markedly until frank joint destruction occurred. Synovial neovascularization was extensive in this model. Synovial vWF microvessel density peaked
2–3 weeks after symptom onset but declined thereafter, as pannus growth outpaced new vessel formation. For synovial thickness, linear regression
analysis yielded a goodness-of-fit (r2) value of 0.815. The microvascular density curve was generated by third-order polynomial nonlinear regression
analysis (r2  0.746). Each symbol represents an individual animal. C–E, Immunohistochemistry analysis of the synovium of mice with CIA, stained
with isotype-matched control antibody (left panels) or target molecule–specific antibody (right panels). Extensive networks of both vWF blood
vessels (C) and LYVE-1 lymphatic vessels (D) are seen, and the inflammatory infiltrate contains large numbers of CD117 putative endothelial
progenitor cells (E). Arrowheads indicate staining with fast red substrate.
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4% increase in Sca-1 cells in the lymphocytic gate of
peripheral blood from animals with arthritis (n  6)
versus control animals (n  4) (P  0.05). In addition to
formation of new vWF synovial blood vessels, we
observed the establishment of new LYVE-1 synovial
lymphatic vessels (Figure 1D). Synovial thickening pro-
gressed such that at 1 month post–symptom onset, the
synovium at the tibial/tarsal juxtaposition was nearly
10-fold thicker in arthritic animals than in nonarthritic
control animals (from a mean  SEM of 56  11 m
thick in control animals to 470  24 m in arthritic
animals; P  0.05). Normal synovial vascularization was
sparse (35  8 vWF vessels/mm2), but vessel density
increased rapidly with disease progression, peaking at
2–3 weeks post–symptom onset (330  60 vessels/
mm2; P  0.05 versus nonarthritic controls), and then
declined as synovial proliferation outpaced neovascular-
ization. Thus, in this arthritis model we found EPC
mobilization and accumulation in the arthritic joint
lining, which was coincident with enhanced synovial
neovascularization.
Homing of EPCs to the inflamed synovium in
antibody-induced arthritis. We used the anti–type II
collagen antibody–induced arthritis model (10) to inves-
tigate homing of exogenously administered EPCs to
synovium at arthritis onset. Murine Lin EPCs were
injected on the day before predicted symptom onset and
were evaluated in joints 5 days later, when inflammation
was maximal. Disease incidence was nearly 100% with
this model, with arthritis severity in the hind limbs
approaching 90% of maximal (Figure 2A), although
disease severity in the front limbs was 50% of maximal
(data not shown). Thus, we analyzed EPC homing to
synovium from the hind ankle. In mouse hind ankles, we
Figure 2. Preferential homing of endothelial progenitor cells (EPCs) to the inflamed synovium in antibody-
induced arthritis. Arthritis was elicited in BALB/c mice, using a cocktail of 4 monoclonal antibodies against type
II collagen on day 0, followed by intraperitoneal injection of lipopolysaccharide on day 3. EPCs derived from
BALB/c mice were injected on day 4 (the day before symptoms generally appear) and were circulated for 5 days.
Disease severity in the hind limbs was scored daily. After the mice were killed, the hind limbs were cryosectioned
and synovial EPCs were enumerated by fluorescence microscopy. A, Mean  SEM arthritis scores (n  8
antibody-treated mice [6 of which were used in subsequent EPC homing studies] and 6 controls). B, Number of
EPCs per high-power field (hpf) in the tibial/tarsal synovial region of arthritic ankles compared with noninflamed
control ankles. Values are the mean and SEM (n  6 mice per group).   P  0.05 versus controls, by Student’s
t-test. C and D, Typical hematoxylin and eosin (H&E)–stained (C) and fluorescence (D) micrographs of serial
sections of inflamed ankles. Arrows indicate dye-tagged EPCs in the synovial inflammatory infiltrate. Color figure
can be viewed in the online issue, which is available at http://www.arthritisrheum.org.
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observed a 4-fold increase in the number of synovial
EPCs in arthritic animals versus controls (n  6 animals
per group) (mean  SEM 15.6  1.1 versus 4.0  0.5
EPCs/10hpf; P  0.05) (Figure 2B). Thus, EPCs selec-
tively homed to inflamed synovium. Figures 2C and D
show typical hematoxylin and eosin–stained and fluores-
cence micrographs of serial sections of inflamed ankles.
Selective homing of EPCs to RA ST in the
SCID/human ST chimera model. After 2 days of EPC
circulation, we evaluated the recruitment of
fluorescence-labeled EPCs to RA ST and normal ST
that had been engrafted into SCID mice. We observed
significantly increased recruitment of human CD34
cells to RA ST versus normal ST grafts (n  5 animals
per group) (mean  SEM 3.2  0.4 versus 1.4  0.3
cells/hpf; P  0.05) (Figure 3A). In another experiment
using human CD133 cells, a more specific marker for
EPCs than CD34 expression alone (11), we observed a
nearly 3-fold increase in EPC recruitment to RA versus
normal human ST (n  5 animals per group) (2.7  0.3
versus 1.1  0.2 EPCs/hpf; P  0.05) (Figure 3B). Thus,
in this in vivo model, human EPCs were selectively
recruited by inflamed human synovium compared with
normal ST.
TNF-induced up-regulation of VCAM-1 and
ICAM-1 expression in RA ST fibroblasts. We observed
both time- and concentration-dependent up-regulation
of VCAM-1 and ICAM-1 in TNF-stimulated RA ST
fibroblasts (Figure 4). Activation for 24 hours with 20
ng/ml TNF resulted in a mean  SEM 4.8  1.4–fold
increase in ICAM-1, and a 10.4  1.8–fold increase in
VCAM-1 surface expression on RA ST fibroblasts,
evaluated by enzyme-linked immunocellular assay (n 
3 experiments). The mean 50% maximum response
concentration was 300 pg/ml TNF for ICAM-1 induc-
tion and 3 ng/ml TNF for VCAM-1 induction. Both
CAMs showed significant induction with TNF starting
at a concentration of 200 pg/ml. Western blotting of RA
ST fibroblast lysates from cells treated with 20 ng/ml
TNF revealed significant induction beginning at 4
hours with both CAMs. ICAM-1 up-regulation was
maximal at 6 hours and began declining by 24 hours
(Figure 4C). VCAM-1 up-regulation was maximal at 4
hours and was maintained at this level through 24
hours (Figure 4D).
Mediation of EPC adhesion to cultured RA ST
fibroblasts by VCAM-1/4 integrin, but not by ICAM-1
or ICAM-2. CD133 EPCs adhered to TNF-activated
RA ST fibroblasts in both a cytokine concentration–
dependent and a time-dependent manner (Figures 5A
and B). Increased adhesion was apparent with 20
pg/ml of TNF, after 18 hours of stimulation. Higher
concentrations of TNF (i.e., 20 ng/ml) resulted in
significantly increased EPC adhesion after 2.5 hours,
which continued to increase through 20 hours. Anti–
VCAM-1 neutralizing antibody completely inhibited
TNF-induced adhesion of EPCs to RA ST fibroblasts, to
levels seen with unstimulated RA ST fibroblasts (Figure
5C). Although anti–ICAM-1 or anti–ICAM-2 alone did
not inhibit EPC adhesion to activated RA ST fibroblasts,
all 3 CAM antibodies combined caused a modest addi-
tional inhibitory effect on adhesion compared with anti–
VCAM-1 alone. Similarly, blocking antibodies against 4
integrin completely abrogated EPC binding to activated
Figure 3. Selective recruitment of endothelial progenitor cells (EPCs)
to rheumatoid arthritis (RA) versus normal human synovium in a
human/SCID mouse chimera model. RA synovial tissue (RA ST) or
normal ST (NLST) was engrafted subcutaneously into SCID mice.
Fifteen days after implantation (CD34 experiment) (A) or 18 days after
implantation (CD133 experiment) (B), 1  106 fluorescence-labeled
human CD34 hematopoietic progenitor cells or CD133 EPCs were
injected intravenously, and were allowed to circulate for 2 days prior to
graft recovery and evaluation. EPCs in cryosections of nonfibrous
regions of synovial grafts were enumerated using a fluorescence
microscope. Both CD34 progenitor cells and CD133 EPCs were
selectively localized to RA ST compared with normal ST. Values are
the mean and SEM (n  4–6 mice per group).   P  0.05 versus
normal ST, by Student’s t-test.
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RA ST fibroblasts, while anti–2 integrin- and anti–L
integrin alone had no significant effect (Figure 5D). Com-
bined treatment with all 3 integrin antibodies resulted in a
modest additional inhibition of EPC adhesion, compared
with that seen with anti–4 integrin alone. These data
demonstrate that the VCAM-1/very late activation antigen
4 (VLA-4) ligand/receptor pair critically mediates EPC
adhesion interactions with RA ST fibroblasts.
Mediation of EPC adhesion to human RA ST
cryosections by VCAM-1/4 integrin. EPC binding to
cultured RA ST fibroblasts is primarily dependent on
VCAM-1 and the VLA-4 integrin subunit 4. We sought
to elucidate the contributions of these molecules to EPC
adhesion to a more heterogeneous substratum, i.e.,
inflamed human RA ST (Figure 6). Anti–VCAM-1 and
anti–4 integrin antibodies caused significant inhibition
of EPC adhesion to RA ST (mean  SEM 43  3% and
53  13%, respectively, of the level of EPC binding to
control antibody–treated RA ST). This suggests that
VCAM-1 and VLA-4 have a major role in mediating
EPC recruitment to inflamed synovium.
DISCUSSION
EPCs were first identified in the adult circulation
in 1999 (12). Since then, bone marrow–derived EPCs
have been shown to play a role in the neovascularization
that occurs in diverse damaged and diseased tissues
(13–16). EPCs comprise a subset of the CD34 hema-
topoietic stem cell bone marrow fraction (17). In hu-
mans, the best EPC marker is the orphan tetraspan
protein CD133 (11). In mice, the best marker profile for
EPCs identified so far is CD117,Sca-1 double-
positive, with no detectable expression of leukocyte
maturation markers (Lin) (18,19). Given the extensive
Figure 4. Intercellular adhesion molecule 1 (ICAM-1) and vascular
cell adhesion molecule 1 (VCAM-1) functional and protein expression
in cytokine-activated rheumatoid arthritis synovial tissue (RA ST)
fibroblasts. RA ST fibroblasts were stimulated with tumor necrosis
factor  (TNF) for up to 24 hours and were then evaluated by
enzyme-linked immunocellular assay (A and B) or Western blotting (C
and D). Both ICAM-1 and VCAM-1 were strongly up-regulated by
TNF, in both a concentration-dependent manner (24-hour stimula-
tion) (A and B) and a time-dependent manner (20 ng/ml TNF) (C
and D). Data shown are from 1 representative experiment of 3
independent experiments conducted with RA ST fibroblasts from
different donors (4–6 replicates per group in enzyme-linked immuno-
cellular assays, and duplicate lanes in Western blots). Values are the
mean and SEM (bar graphs in C and D represent quantitation of the
Western blot results).   P  0.05 versus unstimulated controls
(Con), by Student’s t-test.
Figure 5. Mediation of endothelial progenitor cell (EPC) adhesion to
activated RA ST fibroblasts by VCAM-1/4 integrin interactions, but
not ICAM-1 or -2. TNF induced RA ST fibroblasts to bind EPCs, in
both a concentration-dependent manner (18-hour stimulation) (A) and
a time-dependent manner (20 ng/ml TNF) (B). Inclusion of neutral-
izing antibodies against VCAM-1 completely abrogated TNF-
induced (20 ng/ml, 18 hours) adhesion of EPCs to RA ST fibroblasts,
while inhibition of ICAM-1 or ICAM-2 activity alone had no signifi-
cant effect on EPC binding (C). Anti–4 integrin also completely
negated TNF-induced (20 ng/ml, 18 hours) adhesion of EPCs to RA
ST fibroblasts, while inhibition of 2 integrin or L integrin activity
individually had no significant effect on EPC adhesion (D). Neutral-
izing antibodies were used at 10 g/ml and remained in the assay
media throughout the attachment period. Data shown are from 1
representative experiment of 3 independent experiments conducted
with RA ST fibroblasts from different donors (4–6 replicates per
group). Values are the mean and SEM.   P  0.05 versus no
stimulation (A and B) or versus TNF treatment alone (C and D), by
Student’s t-test. See Figure 4 for other definitions.
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neovascularization that occurs in RA, we hypothesized
that EPCs are recruited to the arthritic synovium, where
they might contribute to expansion of the synovial
microcirculation.
One primary finding in our study was that, in 3
diverse animal models used to investigate cell homing in
arthritis, EPCs preferentially localized to inflamed syno-
vium compared with normal synovium. The murine CIA
model is characterized by marked synovial neovascular-
ization (including lymphatic vessels) that is measurable
within days of symptom onset. Microvascular density is
maximal 2–3 weeks after arthritis onset, after which it
declines as synovial pannus growth outpaces new vessel
formation. In CIA, this hyperproliferative synovium
invades the joint cartilage and underlying bone, ulti-
mately causing frank joint destruction, typically 3
weeks after onset of clinical symptoms. We speculate
that neovascularization slows even while the pannus
continues to enlarge, because the invasive synovium
begins acquiring necessary additional nutrients and ox-
ygen from the marrow cavities of the newly eroded bone.
In the CIA model, we observed CD117 cells in
the inflammatory infiltrate of arthritic joints, whereas we
did not detect cells bearing this EPC marker in the joint
lining of control animals. This correlates well with
earlier observations that the number of EPCs per mm2
identified immunohistologically in postsurgical human
RA ST samples was elevated 25-fold over the number
of EPCs localized in normal ST (6).
We also observed increased numbers of Sca-1
cells in the lymphocytic fraction of the peripheral blood
mononuclear cells of mice with established CIA. In an
earlier study that used a similar CIA model, EPCs were
also elevated in the peripheral blood of mice at the time
of disease onset (20). However, in that study, EPCs were
not elevated prior to the onset of clinically identifiable
symptoms or 1 week after arthritis was established, when
disease severity scores were maximal. In contrast, we
found that EPCs were significantly elevated 2–21 days
post–inflammation onset in animals with arthritis. This
difference could be due to the use of slightly different
CIA induction protocols, or could reflect the fact that
CD117 was used as the EPC-defining marker in the
earlier study (20), whereas we used Sca-1 for EPC
identification in peripheral blood. Nonetheless, taken
together these data suggest that EPCs are mobilized into
the circulation during arthritis pathogenesis, are re-
cruited to the inflamed synovium, and may contribute to
disease progression.
In contrast to the above-mentioned observations
of elevated circulating EPC levels in mouse arthritis
models, studies in humans have shown that EPCs are
decreased in the peripheral blood of patients with active
RA compared with healthy individuals (21,22). Deple-
tion of EPCs from the circulation in RA patients with
established disease reflects their enhanced extravasation
out of the bloodstream and into the inflamed joint.
We used 2 other in vivo models to track exog-
enously administered EPCs to inflamed synovial tissue
in mice. In an anticollagen antibody–induced arthritis
model, murine EPCs accumulated preferentially in in-
flamed joint lining, and were only rarely observed in the
vicinity of unaffected joints. In a human ST/SCID mouse
Figure 6. Mediation of EPC adhesion to RA ST by vascular cell
adhesion molecule 1 (VCAM-1)/4 integrin interactions.
Fluorescence-labeled human EPCs were incubated on rehydrated RA
ST cryosections. After 20 minutes, nonattached EPCs were washed off
and adherent cells were enumerated. A, EPC binding after inclusion of
neutralizing antibodies against either VCAM-1 or 4 integrin in the
adhesion media. All antibodies were used at 10 g/ml and remained in
the adhesion media throughout the attachment period. Addition of
VCAM-1 or 4 integrin neutralizing antibodies resulted in similar
50% inhibition of EPC binding compared with sections that were
incubated with isotype-matched control antibody. RA ST was from 6
different donors in the VCAM-1 studies and from 8 different donors in
the 4 integrin studies. Values are the mean and SEM.   P  0.05
versus control, by Student’s t-test. B, Fluorescence microscopy, show-
ing typical patterns of EPC adhesion to RA ST cryosections treated
with neutralizing antibodies against VCAM-1 or 4 integrin, or
isotype-matched control antibody (original magnification  200). See
Figure 3 for other definitions. Color figure can be viewed in the online
issue, which is available at http://www.arthritisrheum.org.
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chimera, exogenous human EPCs that were injected into
ST-engrafted mice selectively accumulated in RA ST
compared with normal human synovial grafts. Although
these models do not entirely replicate the mechanistic
complexities of human RA, they certainly demonstrate
that EPCs are recruited to inflamed joint tissue.
We sought to elucidate the mechanisms of the
egress of EPCs into inflamed synovium. The inflamma-
tory cytokine TNF is highly expressed in RA joints
(23), and clinical strategies to target TNF have dem-
onstrated its importance in RA (24). TNF induces
many cell types, including RA ST fibroblasts, to express
adhesion molecules and chemokines that recruit leuko-
cytes (25). We used an in vitro adhesion assay to assess
the contribution of specific adhesion molecules to
CD133 EPC adhesion to TNF-activated RA ST
fibroblasts and to RA ST cryosections. Treatment of RA
ST fibroblasts with TNF confirmed the previously
described concentration- and time-dependent induction
of ICAM-1 and VCAM-1 expression on RA ST fibro-
blasts (26), as well as the concomitant increase in
adhesiveness of RA ST fibroblasts for EPCs. Studies
with neutralizing antibodies demonstrated the primary
importance of RA ST fibroblast–expressed VCAM-1,
but not ICAM-1 or -2, in mediating EPC–RA ST
fibroblast binding.
Given that the vast majority of EPCs express the
VCAM-1 counterreceptor (VLA-4) subunit, 4 integrin,
we tested whether antibodies against 4 integrin, or
other integrins, would inhibit EPC adhesion to TNF-
activated RA ST fibroblasts. We observed total abroga-
tion of EPC–RA ST fibroblast binding, to levels ob-
served in control experiments using unstimulated RA ST
fibroblasts, when anti–4 integrin antibody was included
in the adhesion assay. Inhibition of L integrin (a
subunit of the ICAM-1/2 receptor lymphocyte function–
associated antigen 1 [LFA-1]) or of 2 integrin (a
common subunit of LFA-1 and also of the ICAM-1/2
receptor Mac-1), present on certain leukocytes (27), had
no effect on EPC–RA ST fibroblast adhesion. In exper-
iments in which EPC adhesion to cryosections of RA ST
was evaluated, we found a 50% decrease in EPC
adhesion to RA ST sections when either anti–VCAM-1
or anti–4 integrin antibodies were included in the
assay. Together, these results provide evidence of a
major role of the VCAM-1/VLA-4 adhesion system, but
not the ICAM/LFA-1 system, in mediating EPC accu-
mulation in inflamed joint tissue.
There are multiple similarities among the physi-
cal environments in arthritic joints, ischemia-damaged
muscle, and solid tumors (e.g., hypoxia, acidification,
and expression of inflammatory and angiogenic media-
tors) (28). VCAM-1 expression is up-regulated in all of
these conditions (29–31), and all of these tissues recruit
EPCs (15,32–35). The mechanisms by which EPCs home
to these tissues, however, remain poorly elucidated. In
RA models, VCAM-1 regulates B lymphocyte influx into
(36), and survival within (37), the joint. Recently it was
demonstrated that recruitment of CD34 hematopoi-
etic stem cells, the parent population of CD133 EPCs,
into the neovasculature of tumors utilizes the VCAM-1/
VLA-4 adhesive system (38). EPCs are recruited to
ischemia-damaged muscle to reconstitute a functional
microcirculation (32), and ICAM-1 plays a primary role
in EPC recruitment to muscle (39). Ours is the first study
to define the specific participation of the VCAM-1/
VLA-4 system, but not the ICAM/2 integrin subunit
pair, in mediating EPC interactions with synovial cells.
This suggests that the selective use of distinct adhesion
molecules plays a role in recruitment of EPCs to the
synovium during human RA pathogenesis, and high-
lights the mechanistic differences in EPC recruitment in
diverse disease states.
By understanding the mechanisms of EPC re-
cruitment, we can regulate EPC function in humans. In
conditions such as myocardial damage, the goal is to
enhance EPC contributions to neovascularization, with
the desired result of revitalizing the blood supply to the
compromised heart. In the cases of tumorigenesis and
RA, the opposite effect, inhibition of neovascularization
in order to starve and thus inhibit the expansion of
invasive tissue, is the desired effect. A clearer under-
standing of the biologic processes that guide EPCs to the
microcirculatory beds of inflamed and angiogenic tissue
could lead to the development of new tools with which to
modulate these activities.
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